Analyst: Improved market conditions will support Lundbeck's key products in Q1

On Wednesday, when the pharmaceutical firm hands in its first quarterly report for 2022, onlookers should pay attention to four key products, says a Sydbank analyst.
Photo: Lundbeck / PR
Photo: Lundbeck / PR
by marketwire, translated by daniel pedersen

As the pandemic has eased up, and restrictions have been lifted, pharmaceutical firm Lundbeck’s market conditions have improved. This should be evident in the firm’s first quarterly report, which is slated to release on Wednesday, an analyst says.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading